Rymedi is a leader in healthcare applications of the blockchain-powered data management systems. The automated blockchain-powered Quality Management System, implemented through the partnership with Rymedi, will be Med Aditus’ differentiating asset, which will enable capturing, processing, and permissioned sharing of data to ensure quality and integrity of products and processes across manufacturing, distribution, and medication treatment.
This will be the first time that blockchain will be integrated into pharmaceutical manufacturing, distribution, and patient engagement operations in Africa, and likely in the world. Learn more about Rymedi at www.rymedi.com.
Glatt is a global company, specializing in designing and producing machinery for pharmaceutical manufacturing processes. While Glatt makes machinery that is deployed for the traditional batch manufacturing processes, it has been one of the leaders in designing and producing machinery for continuous modular pharmaceutical manufacturing.
Med Aditus Pharmaceuticals, Inc. and Glatt have forged a comprehensive partnership to (i) configure and produce machinery for continuous manufacturing, (ii) develop formulations and manufacture products for regulatory submissions for Med Aditus Pharmaceuticals, Inc. products during early stages of Med Aditus Pharmaceuticals, Inc. operations in Kenya, (iii) train personnel and regulators on the technology, (iv) assist in technology transfer to Med Aditus Pharmaceuticals, Inc.’ Kenya facility, and (v) support maintenance of equipment. Learn more about Glatt at www.glatt.com.
CHEMICAL PROCESS TECHNOLOGY (CPT) PHARMA & MEDICINES FOR ALL INSTITUTE A three-way partnership between CPT Pharma, Medicines for All Institute and Med Aditus Pharmaceuticals, Inc. was forged for the manufacture of selected Active Pharmaceutical Ingredients (APIs) that would be used in our products in Africa.
The CEO of Medicines 4 All Institute, Prof. Frank Gupton at Virginia Commonwealth University, is a leader in developing processes for cost-effective API syntheses from readily available and locally accessible starting materials using continuous manufacturing processes. CPT Pharma in South Africa is implementing continuous manufacturing processes for APIs developed by Prof. Gupton’s group. Learn more about Medicines for All Institute and CPT Pharma at www.vcu.edu/medicines4all/
and chemprotech.co.za.
The Drugs for Neglected Diseases initiative (DNDi) is a highly respected global health organization with an impressive record of bringing forward new medicines and treatments for many neglected diseases, saving millions of lives and improving the quality of life for those afflicted by these diseases in resource-constrained countries.
DNDi and Med Aditus have jointly developed a case study to explore a potential partnership for manufacture of oxfendazole in Africa for its clinical development and marketing upon regulatory approval as an improved treatment for River Blindness (onchocerciasis) and make them available on an affordable and equitable basis. Learn more about DNDi at www.DNDi.org.
© Med Aditus Pharmaceuticals 2024
